Adam Plotkin, MD
Dermatology · Delray Beach, FLNPI 1306896105
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,655 of the $23,507 with a category attached, or 75.1%. 35 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 45.1% of the total. Reporting peaked in 2020 at $11,603 and has fallen 88.7% since, to $1,306 in 2025.
Across 184 payments — averaging $127.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$11K
- Senseonics, Incorporated$8K
- Acera Surgical, Inc.$883
- Organogenesis Inc.$739
- Amgen$491
- AbbVie$429
- plus $2K from 29 others
Across 273 payments — averaging $1930.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$315K
- Bausch Health US, LLC$56K
- Dermavant Sciences, Inc.$48K
- Incyte Corporation$39K
- Arcutis Biotherapeutics, Inc.$37K
- Mindera Corp$23K
- plus $9K from 2 others
What the payments were for
- Speaking & faculty fees$17,65575%
- Travel & lodging$5652%
- Food & beverage$5,25722%
- Education$310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 25 | $10,598 |
| Senseonics, Incorporated | 12 | $8,080 |
| Acera Surgical, Inc. | 6 | $883 |
| Organogenesis Inc. | 19 | $739 |
| Amgen | 16 | $491 |
| AbbVie | 22 | $429 |
| Sanofi | 12 | $347 |
| E.r. Squibb & Sons, L.L.C. | 11 | $325 |
| Kerecis Limited | 5 | $243 |
| Galderma Laboratories, L.p. | 2 | $192 |
| GE HealthCare | 1 | $145 |
| Genentech USA, Inc. | 5 | $87 |
| Strata Skin Sciences, Inc. | 7 | $84 |
| VYNE Pharmaceuticals Inc. | 3 | $83 |
| Biofrontera Inc. | 4 | $74 |
| LEO Pharma Inc. | 4 | $74 |
| Smith+Nephew | 2 | $69 |
| Regeneron Healthcare Solutions, Inc. | 3 | $69 |
| Incyte Corporation | 3 | $52 |
| Elekta, Inc. | 1 | $48 |
| Convatec Inc. | 2 | $47 |
| Almirall LLC | 2 | $42 |
| Novartis | 2 | $40 |
| Johnson & Johnson | 2 | $31 |
| Pfizer | 2 | $31 |
| Arcutis Biotherapeutics, Inc. | 2 | $29 |
| Merz North America, Inc. | 1 | $24 |
| Mimedx Group, Inc. | 1 | $23 |
| DUSA Pharmaceuticals, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $20 |
| UCB, Inc. | 1 | $19 |
| Bristol Myers Squibb | 1 | $19 |
| Tempus AI, Inc | 1 | $18 |
| Chiesi USA, Inc. | 1 | $18 |
| Botanix SB Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ODOMZO$10,140
- Eversense$8,080
- Restrata Wound Matrix$883
- Kerecis SurgiClose$549
- Otezla$276
- PuraPly$249
- NEMLUVIO$171
- ALLIA$145
- Kerecis GraftGuide$137
- Sotyktu$119
- Skyrizi$118
How this compares
$23,507 in reported general payments places this provider in the 85th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CibinqoAbrocitinib | 22 | $129,835 |
| Ketoconazole | 603 | $10,466 |
| Fluorouracil | 137 | $8,156 |
| Clobetasol Propionate | 97 | $6,561 |
| Gentamicin Sulfate | 132 | $4,437 |
| Halobetasol Propionate | 96 | $4,353 |
| Triamcinolone Acetonide | 307 | $4,190 |
| Mupirocin | 285 | $2,316 |
| Metronidazole | 32 | $1,619 |
| Econazole Nitrate | 64 | $1,440 |
| Minocycline Hcl | 43 | $1,262 |
| Hydrocortisone | 170 | $1,134 |
| Clindamycin Phosphate | 29 | $1,095 |
| Betamethasone Dipropionate | 28 | $977 |
| ValacyclovirValacyclovir Hcl | 30 | $962 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerCibinqo | $31 | $129,83522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,147 dermatology providers in Florida.
Other dermatology in Delray Beach
- John StrasswimmerDelray Beach$560K
- Janet AllenbyDelray Beach$459K
- Francesca LewisDelray Beach$175K
- Francisco KerdelMiami$2.1M
- Brad GlickMargate$2M
- Robert KirsnerMiami$1.4M
- John MinniStuart$1.4M
- Gil YosipovitchMiami$1M
- Shino Bay AguileraFt Lauderdale$1M
- Robert SnyderPembroke Pines$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.